en
Scientific article
Review
Open access
French

Dermatologie : dernières avancées des thérapies ciblées dans la dermatite atopique, la pelade et l’urticaire chronique spontanée

Other titleDermatology: latest developments in targeted therapies for atopic dermatitis, alopecia areata and chronic spontaneous urticaria
Published inRevue médicale suisse, vol. 18, no. 767, p. 156-160
Publication date2022-02-02
Abstract

In recent years, a lot of targeted therapies have appeared on the market. The huge choice and rapid development make it sometimes difficult to stay up to date. This article reviews the latest therapies in the field of atopic dermatitis, alopecia areata and chronic spontaneous urticaria. Anti-IL-4 and anti-IL-13 antibodies and, more recently, JAK inhibitors have been proven to be effective for moderate to severe atopic dermatitis. JAK inhibitors seem promising for the treatment of severe alopecia areata. Ligelizumab and nemoli zumab will provide therapeutical options for chronic spontaneous urticaria and prurigo respectively. These breakthroughs will improve the quality of life of people suffering from invalidating dermatitis, at a certain price.

engfre
Keywords
  • Alopecia Areata / drug therapy
  • Chronic Urticaria
  • Dermatitis, Atopic / drug therapy
  • Dermatology
  • Humans
  • Quality of Life
Citation (ISO format)
PILETTA-ZANIN, Aurélie et al. Dermatologie : dernières avancées des thérapies ciblées dans la dermatite atopique, la pelade et l’urticaire chronique spontanée. In: Revue médicale suisse, 2022, vol. 18, n° 767, p. 156–160. doi: 10.53738/REVMED.2022.18.767.156
Main files (1)
Article (Published version)
accessLevelPublic
Identifiers
ISSN of the journal1660-9379
195views
21downloads

Technical informations

Creation01/25/2023 2:26:00 PM
First validation01/25/2023 2:26:00 PM
Update time03/16/2023 10:37:26 AM
Status update03/16/2023 10:37:25 AM
Last indexation01/17/2024 11:01:01 PM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack